EMA CHMP recommends marketing authorisation for Novartis’ PNH treatment
This endorsement is a significant step towards the availability of Fabhalta for PNH patients in Europe. The positive opinion is based on data from two Phase III clinical
Santhera Pharmaceuticals has reported that the China National Medical Products Administration (NMPA) granted priority review for a new drug application (NDA) for vamorolone, for Duchenne muscular dystrophy (DMD).